Peripheral tolerance

KEYTRUDA for Ovarian cancer in 7MM: Market Assessment, Competitive Landscape, Forecasts, and Emerging Insights 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
星期五, 四月 26, 2024
Biotechnology, Health, Oncology, FDA, Safety, SWOT, Carcinoma, EU4, Research, PD-1, Hodgkin lymphoma, Melanoma, Clinical trial, Peripheral tolerance, Cancer, Ovarian cancer, Lung cancer, Pharmaceutical industry

The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets.

Key Points: 
  • The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets.
  • Further, it also consists of future market assessments inclusive of the KEYTRUDA market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
  • Other emerging products for ovarian cancer are expected to give tough market competition to KEYTRUDA and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What are the other emerging products available and how are these giving competition to KEYTRUDA for ovarian cancer?

AMERICAN SKIN ASSOCIATION ANNOUNCES 2023 RESEARCH ACHIEVEMENT AWARDS

Retrieved on: 
星期三, 五月 17, 2023
ASA, AWARD, Oregon Health and Science University Center for Women's Health, ISID, Skin cancer, Public policy, Atopic dermatitis, Research, Keio University, Inflammation, Doctor of Philosophy, Autoimmunity, Homeostasis, Peripheral tolerance, Psoriasis, Oregon Health & Science University, Professor, Pemphigus, International Society for Bipolar Disorders, Melanoma, Allergy, GEORGE, Ponce Health Sciences University, Vitiligo, Skin, Medical device, Dermatology, MD

NEW YORK, May 17, 2023 /PRNewswire/ -- American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan.

Key Points: 
  • MASAYUKI AMAGAI, MD, PhD 2023 RECIPIENT OF GEORGE W. HAMBRICK AWARD
    NEW YORK, May 17, 2023 /PRNewswire/ -- American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan.
  • "ASA is honored to recognize Dr. Hanifin and Dr. Amagai and all the 2023 Research Achievement Award recipients for their tireless efforts in the field of dermatology.
  • Dr. Amagai's clinical and research interests center on autoimmune and allergic skin diseases, skin barrier, and skin immunology.
  • ASA's Research Achievement Awards were instituted in 1989 to help identify established scientists in investigative dermatology and cutaneous biology.

Bright Peak Therapeutics to Present Innovative Best-in-Class and Multifunctional Regulatory T Cell (Treg) Enhancers at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments

Retrieved on: 
星期四, 十月 20, 2022
Peripheral tolerance, SAN, CA, Regulatory T cell, Therapy, Conference, IND, Autoimmune disease, Cytokine, Degenerative disease, Patient, Biotechnology, Tissue, PEGylation, International Conference on Environmental Systems, Technology, Cancer, Mouse, KDA, PEG, Autoimmunity, 2021 Essex County Council election, GLOBE, Huangshan, IL-2, Vaccine, Fine chemical

SAN DIEGO and BASEL, Switzerland, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a privately held biotechnology company developing next-generation multifunctional precision immunotherapies, today announced the presentation of two posters showcasing the potential of its unique chemical protein engineering platform at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments taking place October 20-25, 2022, in Chania, Crete.

Key Points: 
  • Tregs are essential for maintaining peripheral tolerance, preventing autoimmunity and limiting chronic inflammatory diseases.
  • IL-2 is an essential cytokine critical for Treg activation and proliferation, and low-dose IL-2 has demonstrated promising preliminary clinical efficacy in several autoimmune diseases.
  • Abstract Highlights: Bright Peak has developed a cell-free chemical protein synthesis and conjugation platform to rapidly generate optimized antibody-cytokine (immunocytokine, IC) therapeutics within weeks.
  • This suggests that TNF-IL2 IC may exhibit higher local activity in inflamed tissues where TNF is present at high levels.

Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma

Retrieved on: 
星期三, 七月 20, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MSD, Cisplatin, Patient, Infection, Selection, Neoplasm, Peripheral tolerance, Fluorouracil, Creatinine, Diarrhea, MRK, Squamous cell carcinoma, Merck & Co., HPV, Pembrolizumab, TNBC, CRT, PD-L2, Tobacco, NYSE, PD-1, Radiation, Biomarker, Pneumonitis, Incidence, Larynx, Risk, CPS, Adult, Safety, Head, Cancer, HIV disease progression rates, Recurrence, PD-L1, Disease, FDA, Platinum, Fourth grade, EFS, Neck, Survival, Ligand, Death, Prednisone, Mouth, CHL, PD-1 and PD-L1 inhibitors, Nose, Pharmaceutical industry, Vaccine, HNSCC, Cytomegalovirus, Merck

KEYNOTE-412 is a randomized, double-blind Phase 3 trial (ClinicalTrials.gov, NCT03040999 ) evaluating KEYTRUDA with concurrent CRT, followed by KEYTRUDA as maintenance therapy for the treatment of patients with unresected locally advanced HNSCC.

Key Points: 
  • KEYNOTE-412 is a randomized, double-blind Phase 3 trial (ClinicalTrials.gov, NCT03040999 ) evaluating KEYTRUDA with concurrent CRT, followed by KEYTRUDA as maintenance therapy for the treatment of patients with unresected locally advanced HNSCC.
  • Most head and neck cancers are squamous cell carcinomas that begin in the flat, squamous cells that make up the thin surface layer of the structures in the head and neck.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
  • KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection

Retrieved on: 
星期五, 六月 24, 2022
FDA, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MSD, Patient, Research, IIIC, Peripheral tolerance, EC, Fourth grade, Marketing, Growth, Cancer, Pneumonitis, Skin cancer, Royal commission, Princess, Incidence, PD-L2, Recurrence, Melanoma, IIC, Pembrolizumab, MRK, Population, Ageing, CHL, NYSE, Diarrhea, RFS, III, Death, Infection, European Commission, Survival, Adult, Creatinine, Merck & Co., Ligand, Adolescence, Biomarker, IIB, Prednisone, Disease, PD-1, PD-1 and PD-L1 inhibitors, Prognosis, PD-L1, Risk, Selection, Toxicity, TNBC, Safety, Vaccine, Pharmaceutical industry, Medical imaging, Medical device, Merck, EU, Cytomegalovirus

Additionally, the EC approved expanding the indications for KEYTRUDA in advanced (unresectable or metastatic) melanoma and stage III melanoma (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.

Key Points: 
  • Additionally, the EC approved expanding the indications for KEYTRUDA in advanced (unresectable or metastatic) melanoma and stage III melanoma (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.
  • In the EU, KEYTRUDA was previously approved for the treatment of adult patients with advanced (unresectable or metastatic) melanoma and for the adjuvant treatment of adult patients with stage III melanoma and lymph node involvement who have undergone complete resection.
  • Selected KEYTRUDA (pembrolizumab) Indications in the U.S.
    KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB, IIC, or III melanoma following complete resection.

SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

Retrieved on: 
星期二, 六月 21, 2022
Science, Other Science, Biotechnology, Research, General Health, Health, Clinical Trials, Other Health, Reproduction, Population, Vomiting, MHC, Coeliac disease, Epitope, Peripheral tolerance, B cell, Autoimmune disease, Research, TAC, Antigen, Hyperglycemia, Attack, Non-Hodgkin lymphoma, Degenerative disease, Disease, SQZ, Gliadin, Regulatory T cell, Diarrhea, Patient, Abdominal pain, Tacs, Osteoporosis, Nausea, Cirrhosis, NYSE, Autoimmunity, Malnutrition, Vaccine, T1D, Trojan

SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented Tolerizing Antigen Carrier (TACs) nonclinical results at the 2022 Federation of Clinical Immunology Sciences (FOCIS) annual meeting.

Key Points: 
  • SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented Tolerizing Antigen Carrier (TACs) nonclinical results at the 2022 Federation of Clinical Immunology Sciences (FOCIS) annual meeting.
  • The new celiac disease research found that in an in vitro assay, SQZ TACs with deamidated gliadin, a protein associated with celiac disease, resulted in dendritic cell presentation of tolerizing antigens to T cells.
  • In addition, the early data showed that the companys Cell Squeeze process could produce TACs with consistently high levels of antigen.
  • Long-term complications of celiac disease may include malnutrition, accelerated osteoporosis, nervous system problems and issues related to reproduction.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection

Retrieved on: 
星期五, 五月 20, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Royal commission, Cancer, MRK, PD-1 and PD-L1 inhibitors, IIB, Risk, Creatinine, Death, Disease, Ageing, Annual general meeting, PD-L2, Survival, Fourth grade, Ligand, Incidence, Adolescence, Abstract, Infection, European Commission, Patient, IIIC, PD-1, Pneumonitis, Skin cancer, Society, TNBC, American Society of Clinical Oncology, Adult, Peripheral tolerance, CHL, Research, PD-L1, Pembrolizumab, Recurrence, CHMP, European Medicines Agency, Prednisone, III, Selection, Union, ASCO, Biomarker, Growth, European Directive on Traditional Herbal Medicinal Products, Diarrhea, IIC, NYSE, Merck & Co., Melanoma, Vaccine, Pharmaceutical industry, Medical imaging, Medical device, Cytomegalovirus, Merck

Additionally, the CHMP recommended expanding the indications for KEYTRUDA in advanced (unresectable or metastatic) melanoma and stage III melanoma (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.

Key Points: 
  • Additionally, the CHMP recommended expanding the indications for KEYTRUDA in advanced (unresectable or metastatic) melanoma and stage III melanoma (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.
  • 0.00658) in patients 12 years and older with stage IIB and IIC melanoma following complete resection.
  • KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB, IIC, or III melanoma following complete resection.
  • Pneumonitis occurred in 8% (31/389) of adult patients with cHL receiving KEYTRUDA as a single agent, including Grades 3-4 in 2.3% of patients.

2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting

Retrieved on: 
星期五, 四月 8, 2022
Oncology, Health, Genetics, General Health, Research, Science, Biotechnology, Private Securities Litigation Reform Act, Cell, Risk, LinkedIn, Safety, CD20, Peripheral tolerance, Sale, DNA, Investigational New Drug, CD79A, TIME, Loss, Geography, NHL, Lymphoma, IND, CAR, AACR, Research, American Association, Antigen, U.S. Securities and Exchange Commission, HES, TAL, Downregulation and upregulation, Translation, Multiple myeloma, Association, American Association for Cancer Research, Twitter, CBLB, Goal, Diffuse large B-cell lymphoma, Megat Burhainuddin, CD19, Patient safety, Annual report, FDA, Social media, Patient, Disease, Security (finance), Medical imaging, Pharmaceutical industry, Vaccine, Video game console

(Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will present preclinical data on bbT369, an investigational novel CD79a/CD20 dual-targeting CBLB gene edited CAR T cell therapy at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.

Key Points: 
  • (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will present preclinical data on bbT369, an investigational novel CD79a/CD20 dual-targeting CBLB gene edited CAR T cell therapy at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.
  • bbT369 was purposefully designed to potentially address known mechanisms of anti-CD19 CAR T cell therapy failure.
  • CD79a, a novel target, is a critical signaling component of the B cell receptor and CD20 is a known clinical target for lymphoma.
  • bbT369 is an investigational dual-targeting CAR T cell therapy with a gene edit for patients with relapsed and/or refractory B-NHL.

NEUVOGEN Appoints Biotechnology Veteran, Mark Backer, PhD as Head of Technical Operations

Retrieved on: 
星期一, 三月 28, 2022
Risk, Cell, Stem cell, Sigma-Aldrich, University of Washington Department of Global Health, Genentech, Molecular medicine, Cancer, Chemical engineering, Vaccine, Doctor of Philosophy, CMC, Head, Antigen, Neoplasm, CEO, Transfection, TAAS, Peripheral tolerance, Immune system, Knowledge, Bharathidasan University, Eli Lilly, Chemistry, IDEC, Stanford University, SAN, Jennerex, Protein, University, Patient, Merck, Antibody, Pharmaceutical industry, Vaxart, Aviron

SAN DIEGO, March 28, 2022 /PRNewswire/ -- NEUVOGEN, an immunoncology company, announced today that Mark Backer, PhD has joined the company as Head of Technical Operations, and will be responsible for leading all aspects of technical operations and chemistry, manufacturing and controls (CMC) technical development for NEUVOGEN's cancer vaccines.

Key Points: 
  • SAN DIEGO, March 28, 2022 /PRNewswire/ -- NEUVOGEN, an immunoncology company, announced today that Mark Backer, PhD has joined the company as Head of Technical Operations, and will be responsible for leading all aspects of technical operations and chemistry, manufacturing and controls (CMC) technical development for NEUVOGEN's cancer vaccines.
  • Backer's industry experience began in 1978, when he was the seventh employee of Genentech and initiated its pilot manufacturing operations.
  • He has served as Sr. VP, Technical Operations with Jennerex with responsibility for all CMC operations.
  • "I am thrilled to join NEUVOGEN, after serving as a technical advisor for the last four months" said Dr.

Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells to Treat Serious Autoimmune and Inflammatory Diseases

Retrieved on: 
星期三, 六月 23, 2021
Health, Diabetes, Other Health, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Clinical medicine, Immunology, Regulatory T cell, Autoimmunity, Autoimmune disease, T cell, Sjögren syndrome, Peripheral tolerance, Immune privilege

At Abata, were harnessing Tregs as targeted therapies to alter the course of serious autoimmune disease and succeed where others have failed.

Key Points: 
  • At Abata, were harnessing Tregs as targeted therapies to alter the course of serious autoimmune disease and succeed where others have failed.
  • Abatas autologous Treg cell therapies are engineered to express T cell receptors (TCRs) that recognize antigens present in tissue where an autoimmune response has been triggered.
  • This enables Abatas Tregs to target the site of disease for a robust effect without imposing systemic immune suppression.
  • Abatas Treg cell therapy will treat patients with the genetic HLA haplotype DR3, an estimated 75% of patients.